The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy

Therapeutic Advances in Endocrinology and Metabolism

Volumn 3, Issue 1, 2012, Pages 3-9

  Velija Asimi, Zelija ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

acromegaly; human growth hormone; insulin like growth factor I; octreotide; pituitary adenoma

Indexed keywords

HUMAN GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84857854457     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018811434728     Document Type: Article

References (19)

1. Abe T. Lüdecke D.K. (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145: 137–145.
2. Melmed S. Colao A. Barkan A. Molitch M. Grossman A.B. Kleinberg D. et al. (2009) Acromegaly Consensus Group. J Clin Endocrinol Metab 94 (5):1509.
3. Bevan J.S. Atkin S.L. Atkinson A.B. Bouloux P.M. Hanna F. Harris P.E. et al. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-1 and tumor size. J Clin Endocrinol Metab 87: 4554–4563.
4. Biermasz N.R. van Dulken H. Roelfsema F. (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84: 3551–3555.
5. Colao A. Ferone D. Cappabianca P. (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308–3314.
6. Colao A. Ferone D. Marzullo P. Cappabianca P. Cirillo S. Boerlin V. et al. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779–2786.
7. Colao A. Marzullo P. Ferone D. Spinelli L. Cuocolo A. Bonaduce D. et al. (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85: 3132–3140.
8. Colao A. Pivonello R. Auriemma R.S. Briganti F. Galdiero M. Tortora F. et al. (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients J Clin Endocrinol Metab 91: 2112–2118.
9. Colao A. Pivonello R. Galderisi M. Cappabianca P. Auriemma R.S. Galdiero M. et al. (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93: 2639–2646.
10. Cozzi R. Attanasio R. Montini M. Pagani G. Lasio G. Lodrini S. et al. (2003) Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results by ROC analysis. J Clin Endocrinol Metab 88: 3090–3098.
11. Cozzi R. Montini M. Attanasio R. Albizzi M. Lasio G. Lodrini S. et al. (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91: 1397–1403.
12. Giustina A. Barkan A. Casanueva F.F. Cavagnini F. Frohman L. Ho K. et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526–529.
13. Giustina A. Bonadonna S. Bugari G. Colao A. Cozzi R. Cannavo S. et al. (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized controlled trial. Eur J Endocrinol 161: 331–338.
14. Lucas T. Astorga R. Catalá M. and the Spanish Multicentre Lanreotide Study Group on Acromegaly (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 58: 471–481.
15. Melmed S. Casanueva F.F. Cavagnini P. (2002) Consensus: Guidelines for Acromegaly Management. J Clin Endocrinol Metab 87: 4054–4058.
16. Melmed S. Kleinberg D. (2008) Anterior pituitary. In: Ed. Kronenberg H.M. Melmed S. Polonsky K.S. Larsen P.R. (eds), Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; chapter 8.
17. Newman C.B. Melmed S. George A. Torigian D. Duhaney M. Snyder P. et al. (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83: 3034–3040.
18. Stewart P.M. Kane K.F. Stewart S.E. Lancranjan I. Sheppard M.C. (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80: 3267–3272.
19. Swearingen B. Barker F.G. II Katznelson L. Biller B.M. Grinspoon S. Klibanski A. et al. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83: 3419–3426.